ENGN insider buying and SEC filings, explained
enGene Therapeutics Inc. · CIK 1980845
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq, Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- Z4
- Fiscal year end
- Oct 31
- Former names
- enGene Holdings Inc.
Insider activity in the last 12 months
Bought
$10K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 22, 2026 | Purchase (code P) | William Grossman (Interim Chief Medical Officer and Director) bought 5,102 shares at $1.97 ($10K), reported as a purchase (code P). New position of 5,102 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Sep 24, 2026 |
16 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ENGN in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.